


PHARMACEUTICAL 2021

Viking Therapeutics Inc. Rank 25 of 402







PHARMACEUTICAL 2021



Viking Therapeutics Inc. Rank 25 of 402

The relative strengths and weaknesses of Viking Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Viking Therapeutics Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 70% points. The greatest weakness of Viking Therapeutics Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 16% points.

The company's Economic Capital Ratio, given in the ranking table, is 283%, being 236% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	256,104
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,129
Liabilities, Non-Current	29
Other Assets	398
Other Compr. Net Income	-66
Other Expenses	0
Other Liabilities	0
Other Net Income	3,167
Other Revenues	0
Property and Equipment	0
Research and Development	31,931
Selling, General and Administrative Expense	10,731

Output Variable	Value in 1000 USD
Assets	256,502
Liabilities	12,158
Expenses	42,662
Revenues	0
Stockholders Equity	244,344
Net Income	-39,495
Comprehensive Net Income	-39,528
Economic Capital Ratio	283%

